← All trials
NCT04702503
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 8, 2019
- Primary completion
- Nov 15, 2019
- Completion date
- Nov 15, 2020
- First posted
- Jan 11, 2021
- Last posted
- Jan 11, 2021
- Enrollment
- 5
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Moleculin, LLCLead sponsor
- Moleculin, LLCStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.